Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 7/20 | 0.46 |
| ▸ | MLYCD | O95822 | 2/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14506160 | 0.85 | EGFR (0.45) | EGFRERBB2CNR2MLYCDHDAC11 | |
| SCHEMBL1963626 | 0.82 | EGFR (0.53) | EGFRERBB2CNR2HDAC11PTGES | |
| SCHEMBL29138374 | 0.82 | EGFR (0.53) | EGFRERBB2CNR2HDAC11PTGES | |
| SCHEMBL29138335 | 0.82 | EGFR (0.53) | EGFRERBB2CNR2HDAC11PTGES | |
| SCHEMBL29138334 | 0.82 | EGFR (0.53) | EGFRERBB2CNR2HDAC11PTGES | |
| SCHEMBL2369922 | 0.82 | EGFR (0.53) | EGFRERBB2CNR2HDAC11PTGES | |
| SCHEMBL29138331 | 0.82 | EGFR (0.53) | EGFRERBB2CNR2HDAC11PTGES | |
| SCHEMBL29138333 | 0.82 | EGFR (0.53) | EGFRERBB2CNR2HDAC11PTGES | |
| SCHEMBL472312 | 0.81 | PTGES (0.54) | EGFRERBB2CNR2PTGESALOX5 | |
| SCHEMBL11539577 | 0.81 | PTGES (0.54) | EGFRERBB2CNR2PTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070134737-A1 | Fluorophore compounds and their use in biological systems | STANFORD UNIVERSITY (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2005005956-A2 | FLUOROPHORE COMPOUNDS AND THEIR USE IN BIOLOGICAL SYSTEMS | STANFORD UNIVERSITY (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20050009109-A1 | FLUOROPHORE COMPOUNDS AND THEIR USE IN BIOLOGICAL SYSTEMS | STANFORD UNIVERSITY (US) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070134737-A1 | Fluorophore compounds and their use in biological systems | DHODH, DUT, DPYD | EGFR 4494/4885ERBB2 4200/4885CNR2 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.